Skip to content

HLA SUBTYPING IN ANTIBODY MEDIATED LIMBIC ENCEPHALITIS

HLA SUBTYPING IN ANTIBODY MEDIATED LIMBIC ENCEPHALITIS - HLA in limbic encephalitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42370
Enrollment
41
Registered
2015-08-19
Start date
2015-08-22
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain inflammation Limbic encephalitis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Limbic encephalitis due to antibodies to LGI1, Caspr2, NMDAR, GABA-B or GAD65, recently or in the past - Current age > 18 years - Caucasoid race

Exclusion criteria

Exclusion criteria: - Not mentally competent to give informed consent - Patient is withholding informed consent, or objects after initial consent

Design outcomes

Primary

MeasureTime frame
The frequency of HLA-A, B, C, DR and DQ alleles

Secondary

MeasureTime frame
If a specific HLA allele is detected in a subgroup of LGI1 patients, we will analyze whether there are specific patient characteristics or disease characteristics in this subgroup Amendement: analyze the relevant LGI1 epitope (fragment of the protein to which inflammatory cells bind)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)